PMID- 19188163
OWN - NLM
STAT- MEDLINE
DCOM- 20090716
LR  - 20201222
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 15
IP  - 3
DP  - 2009 Feb 1
TI  - A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can 
      elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the 
      growth and spread of Her-2/neu-positive breast tumors.
PG  - 924-32
LID - 10.1158/1078-0432.CCR-08-2283 [doi]
AB  - PURPOSE: The aim of this study was to efficiently design a novel vaccine for 
      human Her-2/neu-positive (hHer-2/neu) breast cancer using the live, attenuated 
      bacterial vector Listeria monocytogenes. EXPERIMENTAL DESIGN: Three recombinant 
      L. monocytogenes-based vaccines were generated that could express and secrete 
      extracellular and intracellular fragments of the hHer-2/neu protein. In addition, 
      we generated a fourth construct fusing selected portions of each individual 
      fragment that contained most of the human leukocyte antigen (HLA) epitopes as a 
      combination vaccine (L. monocytogenes-hHer-2/neu chimera). RESULTS: Each 
      individual vaccine was able to either fully regress or slow tumor growth in a 
      mouse model for Her-2/neu-positive tumors. All three vaccines could elicit immune 
      responses directed toward human leukocyte antigen-A2 epitopes of hHer-2/neu. The 
      L. monocytogenes-hHer-2/neu chimera was able to mimic responses generated by the 
      three separate vaccines and prevent spontaneous outgrowth of tumors in an 
      autochthonous model for Her-2/neu-positive breast cancer, induce tumor regression 
      in transplantable models, and prevent seeding of experimental lung metastases in 
      a murine model for metastatic breast cancer. CONCLUSION: This novel L. 
      monocytogenes-hHer-2/neu chimera vaccine proves to be just as effective as the 
      individual vaccines but combines the strength of all three in a single 
      vaccination. These encouraging results support future clinical trials using this 
      chimera vaccine and may be applicable to other cancer types expressing the 
      Her-2/neu molecule such as colorectal and pancreatic cancer.
FAU - Seavey, Matthew M
AU  - Seavey MM
AD  - Department of Microbiology, University of Pennsylvania, School of Medicine, 
      Philadelphia, Pennsylvania, USA.
FAU - Pan, Zhen-Kun
AU  - Pan ZK
FAU - Maciag, Paulo C
AU  - Maciag PC
FAU - Wallecha, Anu
AU  - Wallecha A
FAU - Rivera, Sandra
AU  - Rivera S
FAU - Paterson, Yvonne
AU  - Paterson Y
FAU - Shahabi, Vafa
AU  - Shahabi V
LA  - eng
GR  - CA105008/CA/NCI NIH HHS/United States
GR  - R41 CA114801-01/CA/NCI NIH HHS/United States
GR  - T32CA09140/CA/NCI NIH HHS/United States
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Peptide Fragments)
RN  - 0 (Vaccines, Synthetic)
SB  - IM
CIN - Clin Cancer Res. 2009 Feb 1;15(3):749-51. PMID: 19188142
MH  - Amino Acid Sequence
MH  - Animals
MH  - Antigens, Neoplasm/immunology
MH  - Breast Neoplasms/genetics/immunology/metabolism/*therapy
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cancer Vaccines/immunology/*therapeutic use
MH  - *Genes, erbB-2
MH  - Genetic Vectors
MH  - HLA-A2 Antigen/*immunology
MH  - Humans
MH  - Listeria monocytogenes/*immunology
MH  - Mice
MH  - Molecular Sequence Data
MH  - Neoplasm Transplantation
MH  - Peptide Fragments/immunology
MH  - Vaccines, Synthetic/*therapeutic use
EDAT- 2009/02/04 09:00
MHDA- 2009/07/17 09:00
CRDT- 2009/02/04 09:00
PHST- 2009/02/04 09:00 [entrez]
PHST- 2009/02/04 09:00 [pubmed]
PHST- 2009/07/17 09:00 [medline]
AID - 15/3/924 [pii]
AID - 10.1158/1078-0432.CCR-08-2283 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2009 Feb 1;15(3):924-32. doi: 10.1158/1078-0432.CCR-08-2283.